Skip to main content
Home Start-Ups

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.

https://otc.duke.edu/wp-content/uploads/2025/03/autm-2025-hill-visit-featured-image.png

Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill

From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.

Read More

https://otc.duke.edu/wp-content/uploads/2025/03/mchutchison-featured.png

Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board

New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.

Read More

https://otc.duke.edu/wp-content/uploads/2025/02/TechCommBootcamp_20250214_0251.jpg

Finding the right fit: inventive Duke students get crash course in commercializing their technologies

Making customer calls and polishing pitches – Duke’s innovation ecosystem collaborates to offer Duke graduate and professional students a hands-on technology commercialization bootcamp.

Read More

https://otc.duke.edu/wp-content/uploads/2025/01/jim-flatt-wide.png

Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies

DMC Technologies is a Duke start-up commercializing sustainable chemistry technology out of the lab of Associate Professor Michael Lynch (BME, Pratt).

Read More

https://otc.duke.edu/wp-content/uploads/2025/01/research-summit-2025-featured-image.png

Interdisciplinarity and impact shine at Duke Research and Innovation Summit 2025

The annual gathering of the Duke research community emphasized how innovators are making an impact through their research.

Read More

https://otc.duke.edu/wp-content/uploads/2025/01/tune-therapeutics-large.png

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).

Read More

https://otc.duke.edu/wp-content/uploads/2025/01/vividion-tavros-acquisition.png

Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

Tavros Therapeutics was co-founded by Eoin McDonnell, graduate of the Duke University Molecular Cancer Biology PhD Program, and Associate Professor Kris Wood (Pharmacology and Cancer Biology, SOM).

Read More

https://otc.duke.edu/wp-content/uploads/2024/12/humacyte-logo-new.png

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Humacyte is a Duke University start-up out of the lab of Dr. Laura Niklason (formerly Anesthesiology, SOM), co-founded with Drs. Juliana Blum and Shannon Dahl.

Read More

https://otc.duke.edu/wp-content/uploads/2024/12/TUSW-Dec-2024-featured-image-v3.jpeg

Duke, UNC, and NC State academics get crash course in building startups

Faculty and students with promising IP developed at Triangle universities were invited to workshop their ideas with the help of serial entrepreneurs.

Read More

1 2 3 35